India
· Delayed Price · Currency is INR Zydus Lifesciences Statistics
Total Valuation
Zydus Lifesciences has a market cap or net worth of INR 1.11 trillion. The enterprise value is 1.12 trillion.
| Market Cap | 1.11T |
| Enterprise Value | 1.12T |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | Jul 26, 2024 |
Share Statistics
Zydus Lifesciences has 1.01 billion shares outstanding. The number of shares has decreased by -0.20% in one year.
| Shares Outstanding | 1.01B |
| Shares Change (YoY) | -0.20% |
| Shares Change (QoQ) | -0.50% |
| Owned by Insiders (%) | 75.08% |
| Owned by Institutions (%) | 14.43% |
| Float | 249.06M |
Valuation Ratios
The trailing PE ratio is 26.67 and the forward PE ratio is 24.02. Zydus Lifesciences's PEG ratio is 1.46.
| PE Ratio | 26.67 |
| Forward PE | 24.02 |
| PS Ratio | 5.39 |
| PB Ratio | 5.58 |
| P/FCF Ratio | n/a |
| PEG Ratio | 1.46 |
Enterprise Valuation
| EV / Earnings | 26.82 |
| EV / Sales | 5.45 |
| EV / EBITDA | 18.93 |
| EV / EBIT | 21.64 |
| EV / FCF | n/a |
Financial Position
| Current Ratio | n/a |
| Quick Ratio | n/a |
| Debt / Equity | 3.72 |
| Debt / EBITDA | 0.14 |
| Debt / FCF | n/a |
| Interest Coverage | 87.44 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Capital (ROIC) | 14.50% |
| Revenue Per Employee | 7.66M |
| Profits Per Employee | 1.56M |
| Employee Count | 26,921 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.85% in the last 52 weeks. The beta is 0.46, so Zydus Lifesciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.46 |
| 52-Week Price Change | +72.85% |
| 50-Day Moving Average | 1,171.06 |
| 200-Day Moving Average | 950.77 |
| Relative Strength Index (RSI) | 37.39 |
| Average Volume (20 Days) | 4,446,188 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Zydus Lifesciences had revenue of INR 206.15 billion and earned 41.93 billion in profits. Earnings per share was 41.49.
| Revenue | 206.15B |
| Gross Profit | 143.10B |
| Operating Income | 50.81B |
| Pretax Income | 54.95B |
| Net Income | 41.93B |
| EBITDA | 58.08B |
| EBIT | 50.81B |
| Earnings Per Share (EPS) | 41.49 |
Balance Sheet
The company has 13.58 billion in cash and 8.22 billion in debt, giving a net cash position of 5.36 billion or 5.32 per share.
| Cash & Cash Equivalents | 13.58B |
| Total Debt | 8.22B |
| Net Cash | 5.36B |
| Net Cash Per Share | 5.32 |
| Equity (Book Value) | 221.02B |
| Book Value Per Share | 197.07 |
| Working Capital | n/a |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
Gross margin is 69.41%, with operating and profit margins of 24.64% and 20.34%.
| Gross Margin | 69.41% |
| Operating Margin | 24.64% |
| Pretax Margin | 26.66% |
| Profit Margin | 20.34% |
| EBITDA Margin | 28.17% |
| EBIT Margin | 24.64% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 3.00, which amounts to a dividend yield of 0.27%.
| Dividend Per Share | 3.00 |
| Dividend Yield | 0.27% |
| Dividend Growth (YoY) | -50.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | n/a |
| Buyback Yield | 0.20% |
| Shareholder Yield | 0.48% |
| Earnings Yield | 3.77% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 6, 2015. It was a forward split with a ratio of 5.
| Last Split Date | Oct 6, 2015 |
| Split Type | Forward |
| Split Ratio | 5 |